RXRX Stock Analysis: Buy, Sell, or Hold?
RXRX - Recursion Pharmaceuticals, Inc. Class A Common Stock
$2.93
-0.11 (-3.62%)
▼
5d:
-11.75%
30d:
-18.61%
90d:
-16.05%
WAIT
LOW Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 11, 2026
0d
Smart Money Accumulation
RXRX is down 11.7% this week, but smart money is accumulating calls. Top strike: $4 2026-06-18 with 15,708 OI. Call ratio: 62% View Scanner →
Strength: 7.0/10
Get Alerted When RXRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
3 traders called RXRX this week
75% bullish • 1 bearish
75% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: RXRX is down 11.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: RXRX is down 11.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: RXRX is currently trading at $2.93, which is considered oversold relative to its 30-day fair value range of $3.18 to $3.60.
Technical Outlook: Technically, RXRX is in a strong downtrend. The price is currently testing key support at $2.96. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.64 (+126.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RXRX is in a strong downtrend. The price is currently testing key support at $2.96. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.64 (+126.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.18 -
$3.60
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
Protect Your Profits
Holding RXRX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.6%)
- BULLISH: Trading 126.7% below Wall St target ($6.64)
- WARNING: Recommendation downgraded due to -11.7% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$3.18 -
$3.60
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.96
Resistance Level
$3.56
Current Trend
Strong Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.33
Wall Street Target
$6.64
(+126.7%)
Revenue Growth (YoY)
-56.1%
Share & Embed Analysis
Last updated: May 15, 2026 10:18 PM ET
Data refreshes hourly during market hours. Next update: 11:18 PM
Data refreshes hourly during market hours. Next update: 11:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RXRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Blake Borgeson
SELL
30000 shares
2026-04-07
Ben R Taylor
SELL
7956 shares
2026-03-17
Najat Khan
SELL
28298 shares
2026-03-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 63 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$73 | 50 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 60 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 42 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 62 BUY |
Advanced RXRX Option Strategies
Professional options setups generated by AI based on today's RXRX price and gamma walls.
